ImageneBio, Inc. — Director's Dealing 2022

Jun 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2022-06-09

Reporting Person: FORMELA JEAN FRANCOIS (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-09	Stock Option (Right to Buy)	$4.85	A	13419	Acquired	2032-06-09	Common Stock (13419)	Direct

Footnotes

F1: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the Reporting Person, a director of the Issuer, resigns from the Board or otherwise ceases to service as a director.

F2: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.